By Steven Scheer JERUSALEM, Jan 28 (Reuters) - Teva Pharmaceutical Industries reported strong quarterly results on Wednesday ...

Teva beat fourth-quarter estimates as drug sales surged, led by Austedo and Ajovy, while the company forecast steady earnings ...

Both ANI Pharmaceuticals ANIP and Teva Pharmaceuticals TEVA operate in the pharmaceutical sector, focusing on generic and specialty medications. ANIP’s operations are split between rare disease ...

Teva Pharmaceuticals TEVA announced a funding agreement with Royalty Pharma plc RPRX, under which the latter will provide up to $500 million to accelerate the development of Teva’s anti-IL-15 antibody ...

Novo Nordisk (NVO) faces a class action suit over claims it ran a pay-for-delay deal with Teva (TEVA) to delay generics for its diabetes drug Victoza. Read more here.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Royalty Pharma plc (NASDAQ: RPRX) announced on Sunday a funding agreement of up to $500 million to accelerate the clinical development of Teva’s ...

Danish pharmaceutical giant Novo Nordisk was hit with a class action lawsuit in New York federal court on Friday for allegedly misusing its patents to maintain a monopoly on its diabetes drug Victoza.

In 2023, Teva made a pledge to bolster its innovative medicines portfolio without leaving behind its century-long legacy as a leading generics drugmaker. Now with its innovative drug franchise ...

-- Product: All strengths of Teva Octreotide for Injectable Suspension Kit (DIN 02503751, 02503778 and 0253786) with the lot numbers noted below. -- Issue: Health products -- Product quality -- What ...